This Article Full Text Full Text (PDF) Publisher's Note Erratum (v25,p1819) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, S. E. Articles by Asmar, L. Search for Related Content PubMed PubMed Citation Articles by Jones, S. E. Articles by Asmar, L. Related Articles Related Correspondence Social Bookmarking                            What's this?

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Stephen E. Jones, Michael A. Savin, Frankie Ann Holmes, Joyce A. O'Shaughnessy, Joanne L. Blum, Svetislava Vukelja, Kristi J. McIntyre, John E. Pippen, James H. Bordelon, Robert Kirby, John Sandbach, William J. Hyman, Pankaj Khandelwal, Angel G. Negron, Donald A. Richards, Stephen P. Anthony, Robert G. Mennel, Kristi A. Boehm, Walter G. Meyer, Lina Asmar

From US Oncology Research, Inc, Houston, TX

Address reprint requests to Stephen Jones, MD, US Oncology Research, Inc, Texas Oncology, PA, 3535 Worth St, 6th Floor, Dallas, TX 75246; e-mail: steve.jones{at}usoncology.com

Purpose The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS).

Patients and Methods Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. Between June 1997 and December 1999, 1,016 patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m², respectively; n = 510) or TC (75 and 600 mg/m², respectively; n = 506), administered intravenously every 3 weeks as adjuvant chemotherapy. Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor–positive disease, were administered after completion of chemotherapy.

Results Both treatment groups (TC and AC) were well balanced with respect to major prognostic factors. Patients were observed through 2005 for a median of 5.5 years. At 5 years, DFS rate was significantly superior for TC compared with AC (86% v 80%, respectively; hazard ratio [HR] = 0.67; 95% CI, 0.50 to 0.94; P = .015). Overall survival rates for TC and AC were 90% and 87%, respectively (HR = 0.76; 95% CI, 0.52 to 1.1; P = .13). More myalgia, arthralgia, edema, and febrile neutropenia occurred on the TC arm; more nausea and vomiting occurred on the AC arm as well as one incident of congestive heart failure.

Conclusion At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC.

Supported by sanofi-aventis, Bridgewater, NJ.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Docetaxel Plus Cyclophosphamide in Adjuvant Breast Cancer
  Cristiano Ferrario and Lawrence C. Panasci
  JCO 2007 25: 4327 [Full Text]

This article has been cited by other articles:

				L. Gianni, L. Norton, N. Wolmark, T. M. Suter, G. Bonadonna, and G. N. Hortobagyi Role of Anthracyclines in the Treatment of Early Breast Cancer J. Clin. Oncol., October 1, 2009; 27(28): 4798 - 4808. [Abstract] [Full Text] [PDF]

				W. M. Sikov, D. S. Dizon, R. Strenger, R. D. Legare, K. P. Theall, T. A. Graves, J. S. Gass, T. A. Kennedy, and M. A. Fenton Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study J. Clin. Oncol., October 1, 2009; 27(28): 4693 - 4700. [Abstract] [Full Text] [PDF]

				D. Robson and S. Verma Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era? Oncologist, October 1, 2009; 14(10): 950 - 958. [Abstract] [Full Text] [PDF]

				K. I. Pritchard Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era? Oncologist, October 1, 2009; 14(10): 959 - 962. [Full Text] [PDF]

				D. Soong, R. Haj, M. G. Leung, R. Myers, B. Higgins, J. Myers, and S. Rajagopal High Rate of Febrile Neutropenia in Patients With Operable Breast Cancer Receiving Docetaxel and Cyclophosphamide J. Clin. Oncol., September 10, 2009; 27(26): e101 - e102. [Full Text] [PDF]

				A. Hurria, F. L. Wong, S. Pal, C. T. Chung, S. Bhatia, J. Mortimer, G. Somlo, S. Hurvitz, D. Villaluna, and A. Naeim Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Trastuzumab in Older Adults with HER-2+ Breast Cancer: A Survey of Oncologists Oncologist, September 1, 2009; 14(9): 883 - 890. [Abstract] [Full Text] [PDF]

				D. Takabatake, N. Taira, F. Hara, T. Sien, S. Kiyoto, S. Takashima, K. Aogi, S. Ohsumi, H. Doihara, and S. Takashima Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients Jpn. J. Clin. Oncol., August 1, 2009; 39(8): 478 - 483. [Abstract] [Full Text] [PDF]

				L. N. Harris, G. Broadwater, M. Abu-Khalaf, D. Cowan, A. D. Thor, D. Budman, C. T. Cirrincione, D. A. Berry, E. P. Winer, C. A. Hudis, et al. Topoisomerase II{alpha} Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013 J. Clin. Oncol., July 20, 2009; 27(21): 3430 - 3436. [Abstract] [Full Text] [PDF]

				F. Penault-Llorca, F. Andre, C. Sagan, M. Lacroix-Triki, Y. Denoux, V. Verriele, J. Jacquemier, M. C. Baranzelli, F. Bibeau, M. Antoine, et al. Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., June 10, 2009; 27(17): 2809 - 2815. [Abstract] [Full Text] [PDF]

				P. J. Barrett-Lee, J. M. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, and M. W. Verrill Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk Ann. Onc., May 1, 2009; 20(5): 816 - 827. [Abstract] [Full Text] [PDF]

				S. Jones, F. A. Holmes, J. O'Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 J. Clin. Oncol., March 10, 2009; 27(8): 1177 - 1183. [Abstract] [Full Text] [PDF]

				L. Gianni and P. Valagussa Anthracyclines and Early Breast Cancer: The End of an Era? J. Clin. Oncol., March 10, 2009; 27(8): 1155 - 1157. [Full Text] [PDF]

				P. G. Morris, H. L. McArthur, C. T. Dang, and C. A. Hudis Selection of Appropriate Patients for Anthracycline Therapy ASCO Educational Book, January 1, 2009; 2009(1): 11 - 18. [Abstract] [Full Text] [PDF]

				D. J. Lenihan and F. J. Esteva Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer Oncologist, December 1, 2008; 13(12): 1224 - 1234. [Abstract] [Full Text] [PDF]

				L. J. Goldstein, A. O'Neill, J. A. Sparano, E. A. Perez, L. N. Shulman, S. Martino, and N. E. Davidson Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197 J. Clin. Oncol., September 1, 2008; 26(25): 4092 - 4099. [Abstract] [Full Text] [PDF]

				D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies Ann. Onc., September 1, 2008; 19(9): 1530 - 1539. [Abstract] [Full Text] [PDF]

				M. Martin, A. Rodriguez-Lescure, A. Ruiz, E. Alba, L. Calvo, M. Ruiz-Borrego, B. Munarriz, C. A. Rodriguez, C. Crespo, E. de Alava, et al. Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer J Natl Cancer Inst, June 4, 2008; 100(11): 805 - 814. [Abstract] [Full Text] [PDF]

				F. Andre, K. Broglio, H. Roche, M. Martin, J. R. Mackey, F. Penault-Llorca, G. N. Hortobagyi, and L. Pusztai Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis J. Clin. Oncol., June 1, 2008; 26(16): 2636 - 2643. [Abstract] [Full Text] [PDF]

				I. J. Dahabreh, H. Linardou, F. Siannis, G. Fountzilas, and S. Murray Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Oncologist, June 1, 2008; 13(6): 620 - 630. [Abstract] [Full Text] [PDF]

				L.-P. P. Tran and J. L. Grabinski Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux Journal of Pharmacy Practice, February 1, 2008; 21(1): 46 - 56. [Abstract] [PDF]

				P. Francis, J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, et al. Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial J Natl Cancer Inst, January 16, 2008; 100(2): 121 - 133. [Abstract] [Full Text] [PDF]

				S. Paik, Y. Taniyama, and C. E. Geyer Jr Anthracyclines in the Treatment of HER2-Negative Breast Cancer J Natl Cancer Inst, January 2, 2008; 100(1): 2 - 4. [Full Text] [PDF]

				M. De Laurentiis, G. Cancello, D. D'Agostino, M. Giuliano, A. Giordano, E. Montagna, R. Lauria, V. Forestieri, A. Esposito, L. Silvestro, et al. Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials J. Clin. Oncol., January 1, 2008; 26(1): 44 - 53. [Abstract] [Full Text] [PDF]

				E. P. Winer, J. R. Harris, B. L. Smith, H. A. D'Alessandro, and E. F. Brachtel Case 32-2007 -- A 62-Year-Old Woman with a Second Breast Cancer N. Engl. J. Med., October 18, 2007; 357(16): 1640 - 1648. [Full Text] [PDF]

				C. Ferrario and L. C. Panasci Docetaxel Plus Cyclophosphamide in Adjuvant Breast Cancer J. Clin. Oncol., September 20, 2007; 25(27): 4327 - 4327. [Full Text] [PDF]

				S. E. Jones In Reply J. Clin. Oncol., September 20, 2007; 25(27): 4327 - 4327. [Full Text] [PDF]

				C. C. Portera and S. M. Swain The Heart of the Matter J. Clin. Oncol., September 1, 2007; 25(25): 3794 - 3796. [Full Text] [PDF]

				H. B. Muss, D. A. Berry, C. Cirrincione, D. R. Budman, I. C. Henderson, M. L. Citron, L. Norton, E. P. Winer, and C. A. Hudis Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience J. Clin. Oncol., August 20, 2007; 25(24): 3699 - 3704. [Abstract] [Full Text] [PDF]

				Doxorubicin or Docetaxel for Operable Breast Cancer? Journal Watch Oncology and Hematology, December 18, 2006; 2006(1218): 2 - 2. [Full Text]